8/1011 sources · 5 publishersUpdated Nov 5, 18:38 UTC
Haemonetics posts Q2 FY2027 earnings beat and lifts full‑year revenue outlook
Haemonetics reported second‑quarter fiscal 2027 revenue of $357.8 million, up 9.3% year over year, and GAAP diluted EPS of $1.00, while adjusted EPS was $1.35. The company raised its full‑year revenue growth guidance to 8%‑11% and organic growth guidance to 6%‑9%, citing expansion of its CSL Persona PLUS rollout. BTIG upgraded its price target to $142, maintaining a Buy rating.
Why it matters
The earnings beat and higher guidance suggest stronger near‑term performance, which could support a price rise; BTIG’s target increase signals analyst optimism.
Key facts
- 1Revenue was $357.8 million, up 9.3% YoY. tradingview.com
- 2GAAP diluted EPS was $1.00. tradingview.com
- 3Adjusted diluted EPS was $1.35. tradingview.com
- 4Gross margin improved to 61.7% from 59.5% a year earlier. tradingview.com
- 5Full‑year revenue growth guidance was raised to 8%‑11% (previously 5%‑8%). tradingview.com
- 6Full‑year organic revenue growth guidance was raised to 6%‑9% (previously 4%‑7%). tradingview.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.